News and Information Home

 


News Features

 


Health+Science Calendar
January 2009
M T W T F S S
« Dec   Feb »
 1234
567891011
12131415161718
19202122232425
262728293031  


Advisory Committee



Thanks to the following sponsor of the WHYY Health+Science Desk:

Philadelphia Healthcare Trust logo

Philadelphia Health Care Trust


 


WHYY's Behavioral Health news reporting is supported by a grant from The Thomas Scattergood Behavioral Health Foundation

Thomas Scattergood Behavioral Health Foundation logo

Health and Science banner

Drugmaker will pay $1.4 billion

January 15th, 2009. Filed under: Health and Science.


By: Taunya English
tenglish@whyy.org

The Department of Justice says Eli Lilly will pay the largest criminal fine ever imposed on an individual corporation in the history of US prosecution.



headphonesListen:

Audio clip: Adobe Flash Player (version 9 or above) is required to play this audio clip. Download the latest version here. You also need to have JavaScript enabled in your browser.

Get the mp3 »

 

Transcript:

The $1.4 billion settlement ends a massive investigation into the promotional practices for Lilly’s antipsychotic drug Zyprexa.

US Attorney Laurie Magid says Lilly urged primary care and nursing home doctors to prescribe Zyprexa for common conditions including sleep disorders and dementia, not approved by the Food and Drug Administration.

Magid: And not just directed at the relatively small number of people in the community that suffer from schizophrenia or bipolar disorder.

Magid says company executives were worried about money and looking for the next big seller to treat a wide group of patients.

She says the pharmaceutical giant violated federal law and continued its marketing practices in the face of warnings that the drug should not be prescribed to elderly patients for dementia.

Magid: Off-label promotion is a serious matter, it can lull physicians into thinking that a drug has been approved by the FDA as safe and effective.

Magid says off-label marketing undermines the Food and Drug Administration approval process designed to protect the public.

Six whistleblowers will share in a portion of the Lilly fine, and hundreds of millions of dollars will be returned to the Medicaid program.

Most commented stories:

1 Response to Drugmaker will pay $1.4 billion

  1. Walking the regulatory line | WHYY News and Information | WHYY

    [...] illegal is this: using marketing to promote off-label uses. That’s where Ely Lilly stepped out of bounds with Zyprexa — promoting the drug in nursing homes. Penn professor and doctor, Garret [...]

Have an comment on this story? Your thoughts are welcome:

spacer image